KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 1.00

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.

Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, David Paez Lopez-Bravo, Julien Taieb, Michalis V Karamouzis, Erika Ruiz-Garcia, Tae Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Qui Tran, Chiara Cremolini, Marwan Fakih

J Clin Oncol 43(19) 2147-2154

PMID40215429
PMCIDPMC12199804
DOI10.1200/JCO-24-02026
发表日期2025-04-11
入排依据:命中用户提供的消化道肿瘤阳性参考集。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). One hundred sixty patients were randomly assigned 1:1:1 to receive sotorasib 960 mg-panitumumab (n = 53), sotorasib 240 mg-panitumumab (n = 53), or investigator's choice (n = 54; crossover permitted after primary analysis). Overall survival (OS) analysis, a key secondary end point, although not adequately powered, was prespecified at 50% maturity (after approximately 80 deaths). In this study, we report the OS, updated overall response rates (ORRs), and data for safety. After a median follow-up of 13.6 months, 24, 28, and 30 deaths occurred in the sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator's choice arms, respectively; updated objective response rates (ORRs; 95% CI) were 30.2% (95% CI, 18.3 to 44.3), 7.5% (95% CI, 2.1 to 18.2), and 1.9% (95% CI, 0.0 to 9.9), respectively. Compared with investigator's choice, the hazard ratios (HRs [95% CI]) for OS were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) with sotorasib 960 mg-panitumumab and 0.83 (95% CI, 0.49 to 1.39; two-sided P = .50) with sotorasib 240 mg-panitumumab. No new safety signals were observed. Although not statistically significant, the observed OS HR and ORR along with prior PFS and safety findings support sotorasib 960 mg-panitumumab as a standard of care in patients with chemorefractory KRAS G12C mCRC.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 2.

FIG 2. OS of sotorasib-panitumumab versus investigator's choice. (A) Kaplan-Meier curves of OS for sotorasib 960 mg-panitumumab (full analysis set). (B) Kaplan-Meier curves of OS for sotorasib 240 mg-panitumumab (full analysis set). (C) Forest plot of sotorasib 960 mg-panitumumab treatment effect on OS in subgroup analyses. (D) Forest plot of sotorasib 240 mg-panitumumab treatment effect on OS in subgroup analyses. The dashed horizontal gray line indicates the median value. Vertical bars indicate censoring. Stratified Cox hazard ratio and stratified log-rank P value for sotorasib-panitumumab versus investigator's choice are provided. The intention-to-treat population included all patients who underwent random assignment. Hazard ratio was not estimated when there were fewer than 10 patients in either treatment arm in a subgroup. HR, hazard ratio; NE, not estimable; OS, overall survival.

A

OS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
B

OS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
KM Figure2 个面板

FIG A2.

FIG A2. OS of sotorasib-panitumumab versus investigator's choice adjusting for control patients receiving subsequent KRAS G12C inhibitor plus EGFR antibody (full analysis set). EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; NE, not estimable.

A

OS

FIG A2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIG A2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span曲线 2:short span
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram of patient disposition. For the sotorasib-panitumumab arms, data on patient numbers continuing treatment (treatment ongoing) represents continuing any component of the doublet for a patient. OS, overall survival.
非 KM Figure
FIG A1.FIG A1. Multiple testing procedure for PFS and OS. OS, overall survival; PFS, progression-free survival.
非 KM Figure
FIG A3.FIG A3. Swimmer plot of duration of response by BICR (responders in the full analysis set). BICR, blinded independent central review; BOR, best overall response; CR, complete response; OS, overall survival; PFS, progression-free survival; PR, partial response.
非 KM Figure